Welcome to our dedicated page for Kymera Therapeutics SEC filings (Ticker: KYMR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kymera Therapeutics filings document the regulatory record of a Nasdaq-listed clinical-stage biotechnology company developing oral small molecule degraders through targeted protein degradation. Its Form 8-K reports cover material events such as operating and financial results, clinical and regulatory disclosures, Regulation FD presentations, collaboration-related updates, and capital-raising arrangements involving common stock.
Proxy and governance filings describe shareholder voting matters, executive compensation, equity awards, board oversight, and bylaw provisions, including forum-selection language. The filing record also identifies KYMR common stock and recurring disclosure areas tied to the company’s pipeline, financing capacity, corporate governance, and public-company reporting obligations.
KYMR notice reports multiple proposed sales of Common Stock by affiliated holders, showing specific sale dates, share quantities, and gross proceeds. The excerpt lists numerous sales by Atlas Venture Fund X, L.P. and related holders, including large transactions on 06/25/2026.
Kymera Therapeutics, Inc. reported that entities associated with director Bruce Booth sold a total of 285,684 shares of Kymera common stock on June 25 in open-market transactions. The sales were executed by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. under a pre-arranged Rule 10b5-1 trading plan adopted on December 11, 2025, and are reported as indirect interests, with Booth disclaiming Section 16 beneficial ownership except for any pecuniary interest.
Kymera Therapeutics, Inc. director-affiliated funds reported sizable open-market sales of common stock. Venture funds associated with director Bruce Booth sold a combined 398,765 shares of Kymera common stock in 30 open-market transactions from June 23–25, 2026. The trades were executed through Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. under a pre-arranged Rule 10b5-1 trading plan adopted on December 11, 2025. Reported sale prices were weighted averages, with individual trades occurring in ranges from about $99.95 to $119.0789 per share. Booth is a member of the general partners of these funds and disclaims Section 16 beneficial ownership except for any pecuniary interest.
Kymera Therapeutics, Inc. had a group of BVF-affiliated reporting persons update their ownership in its securities. The only new transaction was an indirect grant of 6,068 stock options linked to common stock at an exercise price of $99.8700 per share.
These options expire on June 23, 2036 and vest in full on the earlier of June 24, 2027 or the date of Kymera’s next annual stockholder meeting. The filing also restates existing holdings in common shares, previously granted stock options, and pre-funded warrants that are exercisable at $0.0001 per share and do not expire.
Kymera Therapeutics, Inc. director Bruce Booth received a grant of stock options covering 6,068 shares of common stock. The options carry an exercise price of $99.87 per share and expire on June 23, 2036.
These options vest in full on the earlier of June 24, 2027 or the date of Kymera’s next annual stockholder meeting. Following this grant, Booth holds options for 6,068 shares. According to the disclosure, proceeds from any sale of shares issued upon exercise will be transferred to Atlas Venture Life Science Advisors, LLC, and Booth disclaims ownership except to the extent of any pecuniary interest.
Kymera Therapeutics director Gorjan Hrustanovic reported receiving a grant of stock options covering 6,068 shares of Common Stock. The options carry an exercise price of $99.87 per share and expire on June 23, 2036.
The underlying 6,068 shares vest in full on the earlier of June 24, 2027 or the date of Kymera’s next annual stockholder meeting. According to the disclosure, Hrustanovic is a member of BVF Partners L.P. and is obligated to transfer any economic benefit from the sale of shares issued upon exercise of these grants to BVF, and he disclaims beneficial ownership except to the extent of any pecuniary interest.
Kymera Therapeutics director Jeffrey W. Albers received a new stock option grant covering 6,068 shares of common stock. The options have an exercise price of $99.87 per share and expire on June 23, 2036. They vest in full on the earlier of June 24, 2027 or the next annual stockholder meeting. This is a compensation-related award rather than an open-market share purchase or sale.
Kymera Therapeutics Chief Business Officer Noah Goodman reported an exercise-and-sell transaction in company stock. He exercised stock options for 5,000 shares of Common Stock at an exercise price of $21.05 per share, then sold 5,000 shares in two open-market sales at prices of $119.00 and $109.00 per share.
After these transactions, he directly holds 50,195.438 shares of Common Stock and 90,000 stock options. The filing notes that the sales were effected under a pre-arranged Rule 10b5-1 trading plan dated December 10, 2025.
Kymera Therapeutics director Elena Ridloff reported a new equity award. She received a stock option covering 6,068 shares of common stock at an exercise price of 99.87 per share, expiring on June 23, 2036. The option vests in full on the earlier of June 24, 2027 or the next annual stockholder meeting. This is a compensation-related grant, not an open-market purchase or sale, and results in Ridloff holding 6,068 derivative securities directly.
Kymera Therapeutics director Sandor Victor received a new stock option grant. On June 24, 2026, he was awarded options covering 6,068 shares of Kymera common stock with an exercise price of $99.87 per share. These options give him the right to buy shares at that price in the future.
The options expire on June 23, 2036. According to the vesting terms, all 6,068 underlying shares will vest in full on the earlier of June 24, 2027 or the date of Kymera’s next annual meeting of stockholders. After this grant, Victor holds options for 6,068 shares directly.